相关实验视频
Updated: Jan 11, 2026

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.1K
针对α-葡萄糖酶的1,2,4-三抗糖尿病候选药物:比较分析和未来的前景
1Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt.
Future medicinal chemistry
|November 18, 2025
概括
合成的1,2,4-triazole分子通过抑制α-葡萄糖酶酶,显示出作为抗糖尿病剂的显著潜力. 许多衍生品的性能优于现有的药物,为新的糖尿病治疗铺平了道路.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病是由碳水化合物代谢障碍引起的,需要有效的降糖剂.
- 与高血糖相关的并发症是糖尿病管理中的一个主要问题.
- 阿尔法-葡萄糖酶抑制剂是控制血糖水平的关键类型的口服降糖药.
研究的目的:
- 审查1,2,4-triazole衍生物的抗糖尿病潜力,重点关注它们的α-葡萄糖酶抑制活性.
- 探索 1,2,4-triazole 化合物的近期合成策略,以治疗应用.
- 评估这些分子的结构-活性关系 (SAR) 和药物相似性,以便潜在的临床开发.
主要方法:
- 对2020年至2025年间合成的1,2,4-triazole衍生物的文献综述.
- 对α-葡萄糖酶抑制活性,作用机制和SAR的分析.
- 在形方法包括对接研究和药物相似性评估.
- 合成方法和原材料的比较分析.
主要成果:
- 许多1,2,4-三衍生物显示出强大的α-葡萄糖酶抑制.
- 与标准药物Acarbose相比,一些化合物表现出优越的抑制活性.
- SAR分析和对接洞察力为了解抑制机制提供了基础.
- 药物相似性属性表明潜在的临床前和临床评估.
结论:
- 1,2,4-三衍生物代表了开发新型α-葡萄糖酶抑制剂的有希望的支架.
- 用这些化合物准α-葡萄糖酶为管理2型糖尿病提供了可行的策略.
- 这些分子实体的进一步开发可能会导致更安全,更有效的抗糖尿病药物.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
Oral Hypoglycemic Agents: Sulfonylureas
733
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
733
